Turning point therapeutics ceo

On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego. The acquisition follows a March announcement by BMS that it would be moving into 427,000 square feet of R&D; space at Alexandria Point in University Town Center.Aug 01, 2022 · The Wall Street Transcript is a completely unique resource for investors and business researchers. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Aug 16, 2022 · At some point, Flagship decided to combine Senda with Kintai Therapeutics, another startup formed within its labs. ... CEO Guillaume Pfefer said the biotech’s approach was based on insights into ... Leading our call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, as well as a review...May 09, 2022 · On 31 December 2021, I left Alnylam Pharmaceuticals after a 19-year journey as its founding CEO. In this personal reflection, and as Alnylam embarks on its 20 th year as a company leading the RNA ... Aug 09, 2022 · Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully ... Aug 03, 2022 · In this interview, we speak to Dr Tomasz Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product, PhysioMimix™OOC, and how it can accelerate the future of drug ... SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr.SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23 rd Annual Global ...Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23 rd Annual Global ...Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr.Before turning to editorial work in 2008, Katie conducted ethnographic fieldwork focused on technology development, deployment, and use in complex, high-intelligence work organizations. She has studied interdisciplinary expertise, collaboration, and tech-mediated work in both public and private sector organizations in North America, Scandinavia ... Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees. how many youth soccer clubs in us Zacks' free daily newsletter Profit from the Pros provides #1 Rank "Strong Buy" stocks, etfs and more to research for your financial portfolio. SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer ...President & CEO of Turning Point Therapeutics Inc ( 30-Year Financial, Insider Trades) Athena Countouriotis ( insider trades) sold 60,000 shares of TPTX on 02/11/2021 at an average price of $137.48...Aug 09, 2022 · Tenaya Therapeutics in June completed a 94,000-square-foot Genetic Medicines Manufacturing Center in Union City, 30 miles from its headquarters in South San Francisco—where officials in May ... Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees.SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.. In this role, Ms. Yeganegi will lead the global product development team responsible for ...SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer ...Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego. The acquisition follows a March announcement by BMS that it would be moving into 427,000 square feet of R&D; space at Alexandria Point in University Town Center.Ushering in a New Era in Precision Oncology At Turning Point Therapeutics, we are driven to bring differentiated therapies to patients with cancer as rapidly as possible. Our team--including our deep expertise in drug development and design--allow us to do precisely that. A 'turning point' marks a significant and decisive change.Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. Aug 16, 2022 · At some point, Flagship decided to combine Senda with Kintai Therapeutics, another startup formed within its labs. ... CEO Guillaume Pfefer said the biotech’s approach was based on insights into ... SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23 rd Annual Global ...Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.Leading the call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, before turning the...Before turning to editorial work in 2008, Katie conducted ethnographic fieldwork focused on technology development, deployment, and use in complex, high-intelligence work organizations. She has studied interdisciplinary expertise, collaboration, and tech-mediated work in both public and private sector organizations in North America, Scandinavia ... Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees.Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more tikka t1x aftermarket magazine Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally Turning Point Therapeutics (NASDAQ: TPTX) is owned by 82.86% institutional shareholders, 35.16% Turning Point Therapeutics insiders, and 0.00% retail investors. Simeon George is the largest individual Turning Point Therapeutics shareholder, owning 4.25M shares representing 8.48% of the company.President & CEO of Turning Point Therapeutics Inc ( 30-Year Financial, Insider Trades) Athena Countouriotis ( insider trades) sold 60,000 shares of TPTX on 02/11/2021 at an average price of $137.48...On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego. The acquisition follows a March announcement by BMS that it would be moving into 427,000 square feet of R&D; space at Alexandria Point in University Town Center.Aug 09, 2022 · Tenaya Therapeutics in June completed a 94,000-square-foot Genetic Medicines Manufacturing Center in Union City, 30 miles from its headquarters in South San Francisco—where officials in May ... Aug 09, 2022 · NEW HAVEN, Conn., Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ... Aug 03, 2022 · In this interview, we speak to Dr Tomasz Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product, PhysioMimix™OOC, and how it can accelerate the future of drug ... Ushering in a New Era in Precision Oncology At Turning Point Therapeutics, we are driven to bring differentiated therapies to patients with cancer as rapidly as possible. Our team--including our deep expertise in drug development and design--allow us to do precisely that. A 'turning point' marks a significant and decisive change.Aug 16, 2022 · After a brief delay, Bristol Myers Squibb is finally about to close on its $4.1 billion Turning Point acquisition. ... Mark Smith, Finch Therapeutics CEO. August 26, 2022 07:38 AM EDT. seymour police department arrests Before turning to editorial work in 2008, Katie conducted ethnographic fieldwork focused on technology development, deployment, and use in complex, high-intelligence work organizations. She has studied interdisciplinary expertise, collaboration, and tech-mediated work in both public and private sector organizations in North America, Scandinavia ... Aug 15, 2022 · Karyopharm Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings. Price Target Upside/Downside. According to analysts' consensus price target of $10.25, Karyopharm Therapeutics has a forecasted upside of 86.7% from its current price of ... Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more May 09, 2022 · On 31 December 2021, I left Alnylam Pharmaceuticals after a 19-year journey as its founding CEO. In this personal reflection, and as Alnylam embarks on its 20 th year as a company leading the RNA ... Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally Learn about Turning Point Therapeutics (TPTX) stock's management team. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. Home Markets Discover Watchlist Portfolios Screener. Turning Point Therapeutics. NasdaqGS:TPTX Stock Report. Mkt Cap: US$3.8b. Company Overview;President & CEO of Turning Point Therapeutics Inc ( 30-Year Financial, Insider Trades) Athena Countouriotis ( insider trades) sold 60,000 shares of TPTX on 02/11/2021 at an average price of $137.48...Learn about Turning Point Therapeutics (TPTX) stock's management team. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. Home Markets Discover Watchlist Portfolios Screener. Turning Point Therapeutics. NasdaqGS:TPTX Stock Report. Mkt Cap: US$3.8b. Company Overview;Aug 03, 2022 · In this interview, we speak to Dr Tomasz Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product, PhysioMimix™OOC, and how it can accelerate the future of drug ... Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript Published 10 months ago Full Article Onconova Therapeutics, Inc.'s (ONTX) CEO ... trevor story pull hitter Turning Point Therapeutics (NASDAQ: TPTX) is owned by 82.86% institutional shareholders, 35.16% Turning Point Therapeutics insiders, and 0.00% retail investors. Simeon George is the largest individual Turning Point Therapeutics shareholder, owning 4.25M shares representing 8.48% of the company.Legal Name TP Therapeutics, Inc. Stock Symbol NASDAQ:TPTX Company Type For Profit Contact Email [email protected] Phone Number (858)926-5251 Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors ...Aug 09, 2022 · Tenaya Therapeutics in June completed a 94,000-square-foot Genetic Medicines Manufacturing Center in Union City, 30 miles from its headquarters in South San Francisco—where officials in May ... Aug 01, 2022 · The Wall Street Transcript is a completely unique resource for investors and business researchers. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript Published 10 months ago Full Article Onconova Therapeutics, Inc.'s (ONTX) CEO ...Legal Name TP Therapeutics, Inc. Stock Symbol NASDAQ:TPTX Company Type For Profit Contact Email [email protected] Phone Number (858)926-5251 Turning Point Therapeutics is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.Aug 04, 2022 · Key context: CEO Dan Schulman acknowledged inflation’s impact on PayPal’s customers but noted that rising costs might bring more users to solutions like its discount shopping browser extension, Honey. Schulman also said net new active users—which reached 400,000 in Q2—may be affected by economic headwinds. "The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset," said Bristol Myers CEO Giovanni...Leading the call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, before turning the... stolen motorcycle for saleplastic surgery hendersonSAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.. In this role, Ms. Yeganegi will lead the global product development team responsible for ...SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer ...SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr.Leading our call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, as well as a review...Aug 01, 2022 · The Wall Street Transcript is a completely unique resource for investors and business researchers. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Ushering in a New Era in Precision Oncology At Turning Point Therapeutics, we are driven to bring differentiated therapies to patients with cancer as rapidly as possible. Our team--including our deep expertise in drug development and design--allow us to do precisely that. A 'turning point' marks a significant and decisive change.Leading the call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, before turning the...Aug 01, 2022 · The Wall Street Transcript is a completely unique resource for investors and business researchers. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel. SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX ...Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more Zacks' free daily newsletter Profit from the Pros provides #1 Rank "Strong Buy" stocks, etfs and more to research for your financial portfolio. SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23 rd Annual Global ... council properties to rent in cromer Aug 09, 2022 · NEW HAVEN, Conn., Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ... Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally Aug 16, 2022 · After a brief delay, Bristol Myers Squibb is finally about to close on its $4.1 billion Turning Point acquisition. ... Mark Smith, Finch Therapeutics CEO. August 26, 2022 07:38 AM EDT. Aug 09, 2022 · Menlo Park, California, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today announced the successful closing of its fully ... Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally Zacks' free daily newsletter Profit from the Pros provides #1 Rank "Strong Buy" stocks, etfs and more to research for your financial portfolio. bernese mountain dog breeders south dakotastudio flat to rent torquay bills includedrevolutionary war flags 1777 Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript Published 10 months ago Full Article Onconova Therapeutics, Inc.'s (ONTX) CEO ...Ushering in a New Era in Precision Oncology At Turning Point Therapeutics, we are driven to bring differentiated therapies to patients with cancer as rapidly as possible. Our team--including our deep expertise in drug development and design--allow us to do precisely that. A 'turning point' marks a significant and decisive change.Ushering in a New Era in Precision Oncology At Turning Point Therapeutics, we are driven to bring differentiated therapies to patients with cancer as rapidly as possible. Our team--including our deep expertise in drug development and design--allow us to do precisely that. A 'turning point' marks a significant and decisive change.Aug 09, 2022 · NEW HAVEN, Conn., Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ... Aug 04, 2022 · Key context: CEO Dan Schulman acknowledged inflation’s impact on PayPal’s customers but noted that rising costs might bring more users to solutions like its discount shopping browser extension, Honey. Schulman also said net new active users—which reached 400,000 in Q2—may be affected by economic headwinds. Leading the call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, before turning the...Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. Turning Point Therapeutics (NASDAQ: TPTX) is owned by 82.86% institutional shareholders, 35.16% Turning Point Therapeutics insiders, and 0.00% retail investors. Simeon George is the largest individual Turning Point Therapeutics shareholder, owning 4.25M shares representing 8.48% of the company.Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript Published 10 months ago Full Article Onconova Therapeutics, Inc.'s (ONTX) CEO ...SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...Aug 03, 2022 · In this interview, we speak to Dr Tomasz Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product, PhysioMimix™OOC, and how it can accelerate the future of drug ... Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors ...SAN DIEGO, May 14, 2019 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that...Aug 04, 2022 · Key context: CEO Dan Schulman acknowledged inflation’s impact on PayPal’s customers but noted that rising costs might bring more users to solutions like its discount shopping browser extension, Honey. Schulman also said net new active users—which reached 400,000 in Q2—may be affected by economic headwinds. Turning Point Therapeutics (NASDAQ: TPTX) is owned by 82.86% institutional shareholders, 35.16% Turning Point Therapeutics insiders, and 0.00% retail investors. Simeon George is the largest individual Turning Point Therapeutics shareholder, owning 4.25M shares representing 8.48% of the company.Aug 09, 2022 · Tenaya Therapeutics in June completed a 94,000-square-foot Genetic Medicines Manufacturing Center in Union City, 30 miles from its headquarters in South San Francisco—where officials in May ... May 09, 2022 · On 31 December 2021, I left Alnylam Pharmaceuticals after a 19-year journey as its founding CEO. In this personal reflection, and as Alnylam embarks on its 20 th year as a company leading the RNA ... dyfed powys police jobsExecutive Assistant To the CEO at Turning Point Therapeutics. (TPTX) San Diego, CA. Armin Graber, PhD habil. Head of Translational and Precision Medicine Greater Tampa Bay Area ...SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.. In this role, Ms. Yeganegi will lead the global product development team responsible for ...On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego. The acquisition follows a March announcement by BMS that it would be moving into 427,000 square feet of R&D; space at Alexandria Point in University Town Center.Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors ...Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more Learn about Turning Point Therapeutics (TPTX) stock's management team. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership team. Home Markets Discover Watchlist Portfolios Screener. Turning Point Therapeutics. NasdaqGS:TPTX Stock Report. Mkt Cap: US$3.8b. Company Overview;Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors ...SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the Wells Fargo Virtual Healthcare Conference on Sept. 9 and the H.C. Wainwright 23 rd Annual Global ...On June 3, the New York-based global biopharmaceutical company announced it had acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company based in San Diego. The acquisition follows a March announcement by BMS that it would be moving into 427,000 square feet of R&D; space at Alexandria Point in University Town Center. lamotrigine and calcium supplementsSAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors.Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. Home - Turning Point Therapeutics, Inc. Oncology, Meet Precision Developing targeted cancer therapies to mark a turning point in patients' lives. The Human Helping Patients Stay on Their Treatment Path Longer We are seeking to develop cancer treatments that are more precise, effective and longer-lasting. Clinical Trials The ResilienceSAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.. In this role, Ms. Yeganegi will lead the global product development team responsible for ...Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript Published 10 months ago Full Article Onconova Therapeutics, Inc.'s (ONTX) CEO ...Leading our call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update of our business results, as well as a review...SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors.Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees.Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more Aug 01, 2022 · The Wall Street Transcript is a completely unique resource for investors and business researchers. Over 20,000 CEO, Equity Analyst and Money Manager Interviews Jun 15, 2019 · Free press release distribution service from Pressbox as well as providing professional copywriting services to targeted audiences globally top college baseball prospects 2022best akc golden retriever breedersfarming simulator 22 nitrogenlotte world rides xa